0001144204-14-008046.txt : 20140212 0001144204-14-008046.hdr.sgml : 20140212 20140212164841 ACCESSION NUMBER: 0001144204-14-008046 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20140212 DATE AS OF CHANGE: 20140212 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEDGENICS, INC. CENTRAL INDEX KEY: 0001138776 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 980217544 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-86182 FILM NUMBER: 14600996 BUSINESS ADDRESS: STREET 1: C/O MEDGENICS, INC. STREET 2: 435 DEVON PARK DRIVE, BLDG 700 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 1-646-239-1690 MAIL ADDRESS: STREET 1: C/O MEDGENICS, INC. STREET 2: 435 DEVON PARK DRIVE, BLDG 700 CITY: WAYNE STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: MEDGENICS INC DATE OF NAME CHANGE: 20010419 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Pearlman Andrew CENTRAL INDEX KEY: 0001516544 FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: C/O MEDGENICS, INC. STREET 2: 435 DEVON PARK DRIVE BLDG 700 CITY: WAYNE STATE: PA ZIP: 19087 SC 13G/A 1 v368304_sc13ga.htm SCHEDULE 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G/A

(Amendment No. 2)

 

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO § 240.13d-2

 

 

Medgenics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

58436Q203

(CUSIP Number)

 

December 31, 2013

(Date of Event which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)
¨Rule 13d-1(c)
xRule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

1
 

 

CUSIP No.   58436Q203
 
  1.

Names of Reporting Persons

 

Andrew Pearlman

 

 
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  o
    (b)  o
 
  3. SEC Use Only
 
  4. Citizenship or Place of Organization      USA and Israel
 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
5. Sole Voting Power      1,098,343*
 
6. Shared Voting Power      -0-
 
7. Sole Dispositive Power      1,098,343*
 
8. Shared Dispositive Power      -0-

 
  9. Aggregate Amount Beneficially Owned by Each Reporting Person:     1,098,343*
 
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   o
 
  11. Percent of Class Represented by Amount in Row (9)     5.6%**
 
  12. Type of Reporting Person (See Instructions)       IN

 

*Consists of the following securities beneficially owned as of February 12, 2014: (i) 37,062 shares of common stock, 3,500 shares of restricted stock which will vest on January 2, 2015, 45,800 shares of common stock subject to options exercisable at $3.14 per share expiring on September 13, 2014, 92,006 shares of common stock subject to options exercisable at $2.49 per share expiring on September 13, 2014 and 705,190 shares of common stock subject to warrants exercisable at $2.49 per share expiring on March 31, 2016 held directly by the reporting person; (ii) 94 shares of common stock held by the reporting person’s spouse; (iii) 150,000 shares of common stock subject to warrants exercisable at $2.49 per share expiring on March 31, 2016 held by the Pearlman Family Trust U/A/D February 14, 2011, Andrew Pearlman and Debbie Pearlman, as Trustees, for the benefit of the reporting person’s children; (iv) 27,050 shares of common stock subject to warrants exercisable at $2.49 per share expiring on March 31, 2016 held by the Pearlman Friends and Family Trust U/A/D February 14, 2011, Andrew Pearlman and Debbie Pearlman, as Trustees, for the benefit of the reporting person’s family and friends; and (v) 1,719 shares of common stock and 35,922 shares of common stock subject to warrants exercisable at $0.0002 per share expiring on March 31, 2016 held by ADP Holdings LLC, an entity controlled by the reporting person.

 

**Based on 18,689,507 shares of common stock outstanding as of February 12, 2014, as confirmed by the issuer, plus 1,055,968 shares underlying the options and warrants beneficially owned by the reporting person.

 

2
 

Item 1.

 

  (a) Name of Issuer
     
    Medgenics, Inc., a Delaware corporation
     
  (b) Address of Issuer’s Principal Executive Offices
     
    435 Devon Park Drive, Building 700
    Wayne, Pennsylvania 19087

 

Item 2.

 

  (a) Name of Person Filing
     
    Andrew Pearlman
     
  (b) Address of Principal Business Office or, if none, Residence
     
    Andrew Pearlman
    c/o Medgenics, Inc.
    435 Devon Park Drive, Building 700
    Wayne, Pennsylvania 19087
     
  (c) Citizenship
     
    The reporting person is a citizen of the United States of America and Israel.
     
  (d) Title of Class of Securities
     
    Common Stock, par value $0.0001 per share
     
  (e) CUSIP Number
     
    58436Q203

 

Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
  (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
  (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
  (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
  (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

Not Applicable.

3
 

 

Item 4.Ownership

 

(a)Amount beneficially owned: See Row 9 on the cover page hereto.
(b)Percent of class: See Row 11 on the cover page hereto.
(c)Number of shares as to which the person has:
(i)Sole power to vote or direct the vote: See Row 5 on the cover page hereto.
(ii)Shared power to vote or direct the vote: See Row 6 on the cover page hereto.
(iii)Sole power to dispose or to direct the disposition of: See Row 7 on the cover page hereto.
(iv)Shared power to dispose or to direct the disposition of: See Row 8 on the cover page hereto.

 

Item 5.Ownership of Five Percent or Less of a Class


If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: ¨

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person


Not Applicable.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person


Not Applicable.

 

Item 8.Identification and Classification of Members of the Group

 

Not Applicable.

 

Item 9.Notice of Dissolution of Group


Not Applicable.

 

Item 10.Certification


Not Applicable.

 

 

4
 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 12, 2014

 

  /s/ Andrew Pearlman  
  Andrew Pearlman

 

 

 

 

 

5